Lanean...
KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments
KRAS mutations in colorectal and lung cancers predict failure to respond to therapies that target the EGFR. Significant percentages of patients with KRAS wild-type tumors also fail to respond to these therapies. Relapse occurs in patients with KRAS wild-type and mutant tumors, with moderately longer...
Gorde:
| Argitaratua izan da: | Per Med |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5115778/ https://ncbi.nlm.nih.gov/pubmed/27867401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pme.13.1 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|